The bioengineered protein drugs market is experiencing a paradigm shift, with pharmaceutical and biotech companies leveraging advanced biopharmaceuti ...
There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.
Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...
Clinical Trials Arena on MSN2d
Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMRIn Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month ...
Over 1.2 million medical device adverse event reports were not submitted to the US Food and Drug Administration (FDA) within the deadline set by federal regulations, finds an analysis of recent data ...
Sage Therapeutics (NASDAQ:SAGE) stock drops as Bank of America issues an Underperform rating citing an end to Biogen's (BIIB) ...
Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...
Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...
Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...
NICE is seeking public comment on the updated draft guidances through March 27, with plans to issue final draft guidances in July.
Biogen, Eisai’s Leqembi Suffers Overseas Setbacks as UK Denies Coverage, Australia Denies Approval
Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback